Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Wedbush Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $28
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating
Astria Therapeutics Inc | 10-K: FY2024 Annual Report
Astria TherapeuticS GAAP EPS of -$1.68 Beats by $0.01
Astria Therapeutics Inc | 8-K: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics 4Q Research and Development Expenses $20.2M >ATXS
Express News | Astria Therapeutics Inc Qtrly Net Loss per Share $0.44
Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
TD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)
Express News | Citizens Capital Markets Reiterates Market Outperform on Astria Therapeutics, Maintains $26 Price Target
TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $22
Express News | Astria Therapeutics Initiates Alpha-Orbit Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)
JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference